▎Edited by the WuXi AppTec content team
According to incomplete statistics from Innovation Radar, last week (February 12 to February 18), the global health sectorA total of 18 financing events were disclosed, with a total amount exceeding 11 billion yuan.. In terms of amount, there were 13 financings of 100 million yuan or more.According to the disclosed financing rounds, there were 7 early-stage financings (before Series B) and 7 mid-to-late stage financings (Series B and later).Start.10 Companies in the Biopharmaceutical Field Receive Financing, Involving Drug Types Including Cell Therapy, Gene Therapy, Antibody-Drug Conjugates, etc.
#01
Kyverna Therapeutics Goes Public on Nasdaq
Keywords：CAR-T Cell TherapyLatest Financing:Approximately $367 Million IPOOn February 12, Kyverna Therapeutics successfully went public on NASDAQ. Kyverna Therapeutics is a clinical-stage cell therapy research and development company dedicated to developing new therapies for autoimmune and inflammatory diseases. Its therapeutic platform combines T-cell engineering with synthetic biology technology to suppress and eliminate autoreactive immune cells that cause disease. Kyverna Therapeutics’ lead pipeline candidates, KYV-101 and its variant KYV-201, are CAR-T cell therapies designed to treat B-cell-mediated autoimmune diseases. The drug has initiated Phase 1 clinical trials in the United States for lupus nephritis and Phase 1/2 clinical trials in Germany. This financing will advance the clinical development of novel CAR-T cell therapies to address unmet medical needs.
#02
BioAge Labs Completes$170 millionSeries D Financing
Keywords：Small Molecule Targeted DrugsLatest Financing:$170 millionSeries DThis round of investment institutions: Sofinnova Investments, RA Capital, Orbimed, Amgen Ventures, Lilly Ventures, etc.On February 14, BioAge Labs, Inc. announced the completion of a $170 million oversubscribed Series D financing round led by Sofinnova Investments.The funds obtained will be used to support BioAge's Phase 2 clinical development of its investigational drug azelaprag, which will be combined with Eli Lilly's Zepbound (tirzepatide) and other incretin-based therapies for the treatment of obesity. The study of Zepbound is expected to launch in mid-2024 in collaboration with Eli Lilly. Azelaprag is an oral apelin receptor agonist that, when combined with incretin-based drugs, has the potential to help people lose weight without losing muscle mass. In a Phase 1b clinical trial, azelaprag has demonstrated the ability to promote muscle metabolism and increase energy expenditure during bed rest in healthy elderly volunteers, effectively preventing muscle atrophy.
#03
Latigo BiotherapeuticsCompleted$135 Million Series A Financing
Keywords: Small molecule targeted drugsLatest Financing:$135 Million Series AThis round of investment institutions: 5AM Ventures, Corner Ventures, Foresite Capital, Westlake Village BioPartnersOn February 15, Latigo Biotherapeutics announced its emergence from stealth mode and the completion of a $135 million Series A financing round. The company was incubated by Westlake Village BioPartners. The proceeds from this financing will support the continued development of Latigo’s novel pain therapy portfolio, as well as the growth of the company and its platform. LTG-001, an oral, selective Nav1.8 inhibitor developed by Latigo, is currently in Phase 1 clinical trials in healthy volunteers for the treatment of acute and chronic pain. LTG-001 has the potential advantages of rapid onset, significant efficacy, superior safety compared to standard of care, and no impact on the central nervous system, positioning it as a potential "best-in-class" drug.
#04
Profound Bio Completes 1.12USD Billion Series B Financing
Keywords: Antibody-drug conjugatesLatest Financing:1.12USD Billion Series BThis round of investment institutions: OrbiMed, Ally Bridge Group, Janus Henderson Investors, Heartland Healthcare Capital, RA Capital Management, etc.2On the 13th day of the month,Pufang Bio (ProfoundBio) announced the completion of a $112 million Series B financing round to accelerate the development of its Antibody-Drug Conjugate (ADC) pipeline, including advancing the pivotal clinical trial for its ADC product rinatabart sesutecan (Rina-S) for the treatment of ovarian cancer.Pufang BioFocused on developing novel antibody therapies for cancer patients. The company has developed a pipeline of antibody-drug conjugates (ADCs) targeting solid tumors and hematologic malignancies, based on an internally developed, innovative proprietary technology platform. The company’s disclosed development pipeline includes: Rina-S, an ADC targeting folate receptor α (FRα); PRO1160, an ADC targeting CD70; PRO1107, an ADC targeting protein tyrosine kinase 7 (PTK7); and PRO1286, a bispecific ADC targeting multiple solid tumors.
#05
Metagenomi Successfully Listed on NASDAQ
Latest Financing:$93.75 Million IPOOn February 13, Metagenomi successfully went public on Nasdaq. Metagenomi is a gene therapy research and development company. Its technology engine uses cloud computing to identify and improve enzyme systems, including an important enzyme library and next-generation genome editing tools. Based on CRISPR systems, the company is committed to leveraging a toolbox of next-generation gene editing systems to develop potential therapeutic drugs. Through its metagenomics-based discovery platform, the company has uncovered novel cellular mechanisms from previously unknown microorganisms. Metagenomi modifies these naturally evolved systems to transform them into therapeutic tools that can be utilized by partners, powering its pipeline of potential therapeutic drugs. It is reported that the proceeds from this initial public offering will be used for further development of the company’s products.Readers, please star ⭐Chuangjianhui to receive updates第一时间.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media platforms, but unauthorized republication or reproduction in any form by media or institutions is strictly prohibited. For authorization to repost, please contact:"Innovation Insights"Contact us by leaving a message on our WeChat Official Account.
More Data Content RecommendationsClick "InSee", Sharing Chuangjianhui Health New Trends
